Takeda’s David Kerstein Joins Anchiano as Chief Medical Officer

David Kerstein has joined Anchiano Therapeutics as the company’s chief medical officer. Kerstein comes to Anchiano from Takeda Pharmaceutical (OTCMKTS: [[ticker:TKPYY]]), where he was senior medical director of oncology clinical research. Anchiano, which splits its operations between Cambridge, MA, and Jerusalem, Israel, develops cancer drugs. The company’s most advanced compound, inodiftagene vixteplasmid, is in a Phase 2 study testing it as a treatment for non-muscle invasive bladder cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.